Reach Us +44-1753390542
Induction Therapy: A Modern Review of Kidney Transplantation Agents | OMICS International | Abstract
ISSN: 2161-0991

Journal of Transplantation Technologies & Research
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Induction Therapy: A Modern Review of Kidney Transplantation Agents

Cheguevara Afaneh1*, Meredith J Aull1, Sebastian Schubl1,2, David B Leeser1 and Sandip Kapur1

1Department of Surgery, Division of Transplantation, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, USA

2Department of Surgery, Jamaica Hospital, New York, USA

*Corresponding Author:
Cheguevara Afaneh, MD
Department of Surgery, Weill Cornell Medical College
New York Presbyterian Hospital
525 East 68th Street, Box 44
Tel: 212-746-5330
Fax: 212-746-6890
E-mail: [email protected]

Received Date: November 08, 2011; Accepted Date: December 16, 2011; Published Date: December 20, 2011

Citation: Afaneh C, Aull MJ, Schubl S, Leeser DB, Kapur S (2011) Induction Therapy: A Modern Review of Kidney Transplantation Agents. J Transplant Technol Res S4: 001. doi: 10.4172/2161-0991.S4-001

Copyright: © 2011 Ferchichi H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Kidney transplantation remains the most effective modality for the treatment of end-stage renal disease. The development of induction therapy has significantly reduced the incidence of acute rejection within the first six months following kidney transplantation. As a result, induction therapy is typically administered in the majority of kidney transplants. Moreover, early graft function has also improved with the advent and routine administration of induction therapy. Effective induction therapy has also expanded the donor pool as it allows for more effective utilization of marginal donor kidneys including expanded criteria donors and donors after cardiac death. It may also benefit higher immunologic risk recipients such as highly sensitized, African American, and repeat transplant patients. Poly- and monoclonal antibody agents are available for use as induction agents, including rabbit Anti-thymocyte globulin, interleukin-2 receptor antagonists, and alemtuzumab each of which have proven efficacy but have discrete advantages and disadvantages. Tailoring induction therapy to individual patient profiles provides the best opportunity for both short and long-term outcomes of the patient and allograft. Moreover, we explore the role of induction therapy with long-term steroid avoidance immunosuppression regimens in modern kidney transplantation. Overall, we review the safety and efficacy of this important group of induction agents and discuss an approach to tailoring their use for specific patients undergoing kidney transplantation.

Recommended Conferences

4th Annual Summit on Surgery and Transplantation

Singapore, Singapore

International Congress on Gastroenterology and Liver Transplant

Auckland, New Zealand
Share This Page